Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 29(2024), 6 vom: 31. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2024.29.6.2400046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368234282 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368234282 | ||
| 003 | DE-627 | ||
| 005 | 20240214233257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2024.29.6.2400046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368234282 | ||
| 035 | |a (NLM)38333937 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a López-Lacort, Mónica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RSV | |
| 650 | 4 | |a Respiratory Syncytial Virus | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a immunoprophylaxis | |
| 650 | 4 | |a long-acting monoclonal antibodies | |
| 650 | 4 | |a nirsevimab | |
| 650 | 7 | |a nirsevimab |2 NLM | |
| 650 | 7 | |a VRN8S9CW5V |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Muñoz-Quiles, Cintia |e verfasserin |4 aut | |
| 700 | 1 | |a Mira-Iglesias, Ainara |e verfasserin |4 aut | |
| 700 | 1 | |a López-Labrador, F Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Mengual-Chuliá, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-García, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Carballido-Fernández, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Pineda-Caplliure, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Mollar-Maseres, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Shalabi Benavent, Maruan |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz-Herrero, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Zornoza-Moreno, Matilde |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Martín, Jaime Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Alfayate-Miguelez, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Crespo, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Bastida Sánchez, Encarnación |e verfasserin |4 aut | |
| 700 | 1 | |a Menasalvas-Ruiz, Ana Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Téllez-González, Mª Cinta |e verfasserin |4 aut | |
| 700 | 1 | |a Esquiva Soto, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Del Toro Saravia, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz-Muñoz, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Eiros, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Matías Del Pozo, Vanesa |e verfasserin |4 aut | |
| 700 | 1 | |a Toquero-Asensi, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Pastor-Villalba, Eliseo |e verfasserin |4 aut | |
| 700 | 1 | |a Lluch-Rodrigo, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Díez-Domingo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Orrico-Sánchez, Alejandro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 29(2024), 6 vom: 31. Feb. |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:6 |g day:31 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2024.29.6.2400046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 6 |b 31 |c 02 | ||